News
ICCC
4.750
+3.04%
0.140
Weekly Report: what happened at ICCC last week (1216-1220)?
Weekly Report · 3d ago
Weekly Report: what happened at ICCC last week (1209-1213)?
Weekly Report · 12/16 11:21
Immucell Announces Leadership Transition and Strategic Plans
TipRanks · 12/09 21:33
Weekly Report: what happened at ICCC last week (1202-1206)?
Weekly Report · 12/09 11:20
Zacks Initiates Coverage of ImmuCell With Neutral Recommendation
NASDAQ · 12/04 12:49
Weekly Report: what happened at ICCC last week (1125-1129)?
Weekly Report · 12/02 11:20
Weekly Report: what happened at ICCC last week (1118-1122)?
Weekly Report · 11/25 11:12
ImmuCell Q3 Earnings Decline Y/Y, Sales Grow Amid Margin Challenges
NASDAQ · 11/19 16:20
Weekly Report: what happened at ICCC last week (1111-1115)?
Weekly Report · 11/18 11:09
ImmuCell Reports Strong Sales Growth in Q3 2024
TipRanks · 11/15 04:11
ImmuCell Corporation Quarterly Report (Form 10-Q)
Press release · 11/13 22:11
ImmuCell Q3 GAAP EPS $(0.09) Up From $(0.12) YoY, Sales $6.01M Up From $5.40M YoY
Benzinga · 11/13 21:41
IMMUCELL CORPORATION Q3 BASIC EPS USD -0.09
Reuters · 11/13 21:05
IMMUCELL ANNOUNCES UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2024
Reuters · 11/13 21:05
Press Release: ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2024
Dow Jones · 11/13 21:05
More
Webull provides a variety of real-time ICCC stock news. You can receive the latest news about Immucell through multiple platforms. This information may help you make smarter investment decisions.
About ICCC
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing Immediate Immunity against each of the three causes of calf scours (E. coli, coronavirus, and rotavirus).